L’ADN des membres AFSSI
Active Biomarkers, qui sont-ils ?
At Active Biomarkers our mission is to help biotech and pharma companies generate meaningful and actionable data from their unique and precious biological samples (either pre-clinical or clinical), to document the mechanism of action, safety, and efficacy of their innovative therapies.
For this, we leverage our decades of experience in developing, validating, and implementing immunoassays to monitor, biomarkers, evaluate immunogenicity, and analyze the pharmacokinetics and the pharmacodynamics of the drug candidates.
As a team of scientists, we position ourselves as true partners. We handle each project as if it was ours, carefully questioning the scientific and clinical rationale, not to mention real-life practical constraints of each project, to propose what we believe is the most suitable solution.
Finally, our strong track-record in infectious disease, immuno-oncology, inflammatory and auto-immune diseases, and neurological diseases, allows our partners to avoid and overcome usual pitfalls encountered in clinical development.
L’actualité d’Active Biomarkers
Active Biomarkers has been purchased by Kansas City, KS metro – (BUSINESS WIRE)— KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners.
Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities.
This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries.
Membre AFSSI et fier de l’être
Vous êtes membre AFSSI et souhaitez partager votre actualité ?
N’hésitez pas à nous contacter !